Literature DB >> 16314000

EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.

Hidefumi Sasaki, Katsuhiko Endo, Kotaro Mizuno, Motoki Yano, Ichiro Fukai, Yosuke Yamakawa, Yoshitaka Fujii.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16314000     DOI： 10.1016/j.lungcan.2005.09.004

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  4 in total

1.  Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue.

Authors:  Yohei Miyamae; Kimihiro Shimizu; Yasumasa Mitani; Takuya Araki; Yuki Kawai; Masaru Baba; Seiichi Kakegawa; Masayuki Sugano; Kyoichi Kaira; Alexander Lezhava; Yoshihide Hayashizaki; Koujirou Yamamoto; Izumi Takeyoshi
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

2.  High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.

Authors:  Michael Krypuy; Genni M Newnham; David M Thomas; Matthew Conron; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2006-12-21       Impact factor: 4.430

3.  Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.

Authors:  Marileila Varella-Garcia
Journal:  Diagn Pathol       Date:  2006-08-15       Impact factor: 2.644

4.  Prognosis of recurrent non-small cell lung cancer following complete resection.

Authors:  Hidefumi Sasaki; Ayumi Suzuki; Tsutomu Tatematsu; Masayuki Shitara; Yu Hikosaka; Katsuhiro Okuda; Satoru Moriyama; Motoki Yano; Yoshitaka Fujii
Journal:  Oncol Lett       Date:  2014-02-07       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.